Samuel Lee, MD
Ophthalmology · Sacramento, CANPI 1306173893
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,813 of the $200,360 with a category attached, or 62.8%. 25 manufacturers reported payments, led by Alcon at 36.7% of the total. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 499 payments — averaging $401.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$74K
- Dompe US, Inc.$71K
- Glaukos Corporation$31K
- Biotissue Holdings Inc.$19K
- Johnson & Johnson Surgical Vision, Inc.$2K
- AbbVie$1K
- plus $3K from 19 others
Across 106 payments — averaging $2914.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$273K
- Sun Pharmaceutical Industries Inc.$28K
- Alcon Research LLC$7K
What the payments were for
- Consulting fees$25,54313%
- Speaking & faculty fees$125,81363%
- Travel & lodging$15,5718%
- Food & beverage$16,0308%
- Education$1,0000%
- Other$16,4038%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 190 | $73,570 |
| Dompe US, Inc. | 101 | $70,626 |
| Glaukos Corporation | 45 | $31,223 |
| Biotissue Holdings Inc. | 25 | $18,728 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $1,609 |
| AbbVie(2 entities) | 34 | $1,456 |
| Novartis | 18 | $624 |
| Rxsight Inc | 12 | $362 |
| Shire North American Group Inc | 3 | $256 |
| Apellis Pharmaceuticals, Inc. | 3 | $234 |
| Oyster Point Pharma, Inc. | 12 | $232 |
| Mallinckrodt Hospital Products Inc. | 8 | $192 |
| Bausch & Lomb Americas Inc. | 9 | $183 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $164 |
| Sun Pharmaceutical Industries Inc. | 8 | $155 |
| Kala Pharmaceuticals, Inc. | 1 | $147 |
| Astellas Pharma US Inc | 1 | $123 |
| Aerie Pharmaceuticals, Inc. | 1 | $115 |
| Stimlabs LLC | 1 | $85 |
| Amgen(2 entities) | 4 | $76 |
| Rayner Intraocular Lenses Limited | 3 | $71 |
| Sight Sciences, Inc. | 2 | $42 |
| Harrow Eye, LLC | 2 | $41 |
| Tarsus Pharmaceuticals, Inc. | 2 | $31 |
| Thea Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$69,308
- Clareon$58,253
- Prokera$18,460
- AmnioGraft$15,164
- AmnioGuard$7,008
- AcrySof IQ VIVITY IOL$6,860
- Epioxa$6,000
- CE-marked KXLA system$4,739
- AcrySof IQ PanOptix$1,828
- Travoprost Intraocular Implant - iDose$1,643
- Tecnis Symfony IOL$1,500
- KXL System$1,200
- ARGOS$1,112
- Clareon PanOptix Pro$275
- Rocklatan$238
- Rhopressa$238
- XIIDRA$234
- Syfovre$210
- iDose TR$160
- INVELTYS$147
How this compares
$200,360 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 17 | $461,941 |
| XiidraLifitegrast | 95 | $107,910 |
| RestasisCyclosporine | 36 | $45,074 |
| Prednisolone Acetate | 859 | $39,370 |
| Cyclosporine | 71 | $38,664 |
| Fluorometholone | 166 | $12,764 |
| Restasis MultidoseCyclosporine | 18 | $12,478 |
| Doxycycline Hyclate | 182 | $5,638 |
| Ofloxacin | 534 | $5,392 |
| RhopressaNetarsudil Mesylate | 12 | $3,909 |
| ValacyclovirValacyclovir Hcl | 60 | $2,954 |
| Ketorolac Tromethamine | 70 | $2,659 |
| Loteprednol Etabonate | 19 | $2,453 |
| MoxifloxacinMoxifloxacin Hcl | 97 | $2,434 |
| Difluprednate | 15 | $1,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $70,626 | $461,94117 claims |
| Bausch & Lomb Americas Inc.Xiidra | $183 | $107,91095 claims |
| AbbVieRestasis, Restasis Multidose | $1,456 | $57,55254 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $115 | $3,90912 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $164 | $2,45319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Sacramento
- Richard LewisSacramento$262K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.